- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
H Lundbeck (HLUNb)
H Lundbeck stock price live, this page displays CSE HLUNb stock exchange data. View the HLUNb premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the H Lundbeck real time stock price chart below.
What Is the H Lundbeck Stock Price Today?
The H Lundbeck stock price today is 53.95.
What Is the Stock Symbol for H Lundbeck?
The stock symbol for H Lundbeck is "HLUNb."
What Stock Exchange Does H Lundbeck Trade On?
H Lundbeck is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck a Good Stock to Buy?
Determining whether H Lundbeck, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLUNb quote. (ISIN: DK0061804770)
What Is the H Lundbeck Stock Price Today?
The H Lundbeck stock price today is 53.95.
What Is the Stock Symbol for H Lundbeck?
The stock symbol for H Lundbeck is "HLUNb."
What Stock Exchange Does H Lundbeck Trade On?
H Lundbeck is listed and trades on the Copenhagen stock exchange.
Is H Lundbeck a Good Stock to Buy?
Determining whether H Lundbeck, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLUNb quote. (ISIN: DK0061804770)
53.95
-0.20(-0.37%)
Real-time Data·
Fair Value
An estimate of a H Lundbeck's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
53.75
54.20
52 wk Range
35.30
55.35
Earnings results expected in 8 days
1/2
Fair Value
An estimate of a H Lundbeck's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
53.7554.20
52 wk Range
35.3055.35
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HLUNb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a H Lundbeck's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
50.13
Downside
-7.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 4 consecutive years
Why is H Lundbeck stock falling today?- Investing.com
Why is H Lundbeck stock rallying today?- Investing.com
H Lundbeck B receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
5 Buy
6 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 50.13
(-7.09% Downside)
Earnings
Latest Release
Aug 19, 2026
EPS / Forecast
1.16 / 1.12
Revenue / Forecast
6.46B / 6.19B
Compare HLUNb to Peers and Sector
Metrics to compare | HLUNb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHLUNbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.5x | 17.8x | −0.2x | |
PEG Ratio | 0.93 | 0.00 | 0.00 | |
Price/Book | 2.0x | 2.5x | 2.6x | |
Price / LTM Sales | 2.0x | 2.8x | 2.8x | |
Upside (Analyst Target) | −6.9% | 11.4% | 65.5% | |
Fair Value Upside | Unlock | 12.3% | 8.9% | Unlock |
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the H Lundbeck (HLUNb) Stock Price Today?
The H Lundbeck stock price today is 53.95 DKK.
What Stock Exchange Does H Lundbeck Trade On?
H Lundbeck is listed and trades on the Copenhagen Stock Exchange.
What Is the Stock Symbol for H Lundbeck?
The stock symbol for H Lundbeck is "HLUNb."
What Is the H Lundbeck Market Cap?
As of today, H Lundbeck market cap is 52.77B DKK.
What Is H Lundbeck's Earnings Per Share (TTM)?
The H Lundbeck EPS (TTM) is 3.97.
When Is the Next H Lundbeck Earnings Date?
H Lundbeck will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is HLUNb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has H Lundbeck Stock Split?
H Lundbeck has split 0 times.
How Many Employees Does H Lundbeck Have?
H Lundbeck has 5000 employees.
What is the current trading status of H Lundbeck (HLUNb)?
As of Nov 03, 2026, H Lundbeck (HLUNb) is trading at a price of 53.95 DKK, with a previous close of 54.15 DKK. The stock has fluctuated within a day range of 53.75 DKK to 54.20 DKK, while its 52-week range spans from 35.30 DKK to 55.35 DKK.
What Is H Lundbeck (HLUNb) Price Target According to Analysts?
The average 12-month price target for H Lundbeck is 50.13 DKK, with a high estimate of 62 DKK and a low estimate of 36 DKK. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -7.09% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.